SLG
RPRX icon

Stanley-Laman Group’s Royalty Pharma RPRX Stock Holding History

Stanley-Laman Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Sell
48,978
-308
-0.6% -$16K 0.28% 116
2026
Q1 		$2.36M Buy
+49,286
New +$2.16M 0.29% 120

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stanley-Laman Group's RPRX Position: Q2 2026 in Review

Stanley-Laman Group reduced its Royalty Pharma (RPRX) stake by 0.62% in Q2 2026, selling an estimated $16K and leaving 48,978 shares worth $2.75M. The position accounts for 0.28% of the portfolio, ranked #116.

Stanley-Laman Group first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Stanley-Laman Group held 48,978 shares of Royalty Pharma worth $2.75M as of Q2 2026.
  • Stanley-Laman Group sold 308 Royalty Pharma shares in Q2 2026, an estimated $16K.
  • Royalty Pharma made up 0.28% of Stanley-Laman Group's portfolio in Q2 2026, its #116 holding.
  • Stanley-Laman Group first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.